Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

770
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
770
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

1.2K
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
1.2K
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

3.3K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
3.3K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

1.3K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
1.3K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

When the usual spaces fail: the role of L5-S1 spinal anesthesia in the difficult spine.

Korean journal of anesthesiology·2026
Same author

Improving Delirium Prediction in Surgery: Enhanced Machine Learning Models vs. Traditional Risk Scores.

Journal of Korean medical science·2026
Same author

Abnormal body weight and risk of gallbladder cancer: an updated meta-analysis incorporating recent evidence.

BMC cancer·2026
Same author

Acellular Dermal Matrix (WITHderm<sup>®</sup>) Spacer Grafts for the Prevention of Lower Eyelid Ectropion After Subciliary Approaches in Facial Fracture Surgery: A Preliminary Study.

Journal of functional biomaterials·2026
Same author

Patient-controlled analgesia in transition: opioid-sparing strategies and the emergence of mechanism-based alternatives.

Korean journal of anesthesiology·2026
Same author

Retrospective Analysis of 50 Hemi-Keystone Flap Head and Neck Reconstructions with Scar Assessment.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Apr 27, 2026

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

1.9K

Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine

Kyu Nam Kim1, Kyo Sang Kim1, Hoon Il Choi1

  • 1Department of Anesthesiology and Pain Medicine, Hanyang University School of Medicine, Seoul, Korea.

Korean Journal of Anesthesiology
|July 10, 2014
PubMed
Summary

Rocuronium precurarization effectively reduces succinylcholine-induced muscle fasciculations. An optimal dose of 0.04 mg/kg rocuronium minimizes fasciculations and myalgia while maintaining an acceptable onset time for succinylcholine.

Keywords:
FasciculationMyalgiaNeuromuscular blockadePrecurarizationRocuroniumSuccinylcholine

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.5K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

Related Experiment Videos

Last Updated: Apr 27, 2026

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

1.9K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.5K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Neuromuscular blockade

Background:

  • Succinylcholine administration frequently causes muscle fasciculations and myalgia.
  • Rocuronium is a neuromuscular blocking agent used to mitigate these adverse effects.
  • Optimizing rocuronium dosage is crucial for balancing efficacy and safety.

Purpose of the Study:

  • To determine the optimal dose of rocuronium for preventing succinylcholine-induced fasciculations and myalgia.
  • To assess the impact of varying rocuronium precurarization doses on succinylcholine's onset of action.

Main Methods:

  • A randomized, double-blind study involving 100 patients.
  • Five groups received different rocuronium precurarization doses (0.02–0.06 mg/kg).
  • Neuromuscular blockade was monitored using acceleromyography; fasciculations and myalgia were assessed.

Main Results:

  • Increasing rocuronium doses significantly reduced the incidence and severity of muscle fasciculations (P < 0.001).
  • Myalgia incidence showed a decreasing trend with higher rocuronium doses, though not statistically significant (P = 0.072).
  • The onset time of succinylcholine was significantly prolonged with increasing rocuronium doses (P < 0.001).

Conclusions:

  • Precurarization with 0.04 mg/kg rocuronium is identified as the optimal dose.
  • This dose effectively reduces fasciculation and myalgia incidence and severity.
  • The 0.04 mg/kg dose offers a safe and effective precurarization strategy with acceptable succinylcholine onset time.